About Radius Health (NASDAQ:RDUS)
Radius Health, Inc. is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company's lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Company's clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its RAD140 is a non-steroidal, selective androgen receptor modulator (SARM). RAD140 is under development for potential use in hormone receptor positive breast cancer.
Industry, Sector and Symbol
Trailing P/E Ratio-6.06550678360899
Forward P/E Ratio-6.97
Sales & Book Value
Annual Sales$22.11 million
Price / Sales71.73
Price / CashN/A
Book Value$5.43 per share
Price / Book6.48
Return on Equity-99.97%
Return on Assets-67.64%
Radius Health (NASDAQ:RDUS) Frequently Asked Questions
What is Radius Health's stock symbol?
Radius Health trades on the NASDAQ under the ticker symbol "RDUS."
How were Radius Health's earnings last quarter?
Radius Health Inc (NASDAQ:RDUS) posted its quarterly earnings results on Thursday, March, 1st. The biopharmaceutical company reported ($1.59) EPS for the quarter, missing analysts' consensus estimates of ($1.43) by $0.16. The biopharmaceutical company had revenue of $7.66 million for the quarter, compared to analyst estimates of $7.37 million. The company's revenue for the quarter was up 666.0% on a year-over-year basis. During the same period last year, the firm earned ($1.22) EPS. View Radius Health's Earnings History.
Where is Radius Health's stock going? Where will Radius Health's stock price be in 2018?
10 brokerages have issued 1 year price targets for Radius Health's shares. Their predictions range from $24.00 to $85.00. On average, they expect Radius Health's stock price to reach $52.22 in the next year. View Analyst Ratings for Radius Health.
What are Wall Street analysts saying about Radius Health stock?
Here are some recent quotes from research analysts about Radius Health stock:
- 1. According to Zacks Investment Research, "Radius received a major boost with the approval of Tymlos for the treatment of postmenopausal women with high risk osteoporosis for fracture. Although the osteoporosis market has a great potential as approximately 1.4 million postmenopausal women in the United States experience an osteoporotic fracture each year, Tymlos is expected to face significant competition from Eli Lilly &Co's Forteo and Amgen’s Prolia. Further, the company suffered a setback when the CHMP issued a second Day-180 List of Outstanding Issues to its MAA for Eladynos in Europe. The CHMP will issue a third Day-180 List of Outstanding Issues in its regulatory review of abaloparatide-SC. While Radius' efforts in developing its pipeline are encouraging, we note that most of its candidates are in their early or mid stages of development. The company’ shares have underperformed the industry in the last twelve months." (1/8/2018)
- 2. Canaccord Genuity analysts commented, "Date and time of first dissemination: July 31, 2017, 12:01 ET Date and time of production: July 31, 2017, 12:01 ET Target Price / Valuation Methodology: Radius Health – RDUS Our $85 price target is based on a probability adjusted EV/S methodology." (7/31/2017)
- 3. Cantor Fitzgerald analysts commented, "RDUS shares are rallying this morning (+2%) on FDA approval of TYMLOS (abaloparatide-SC) ahead of expectations, as the extended PDUFA was June." (4/28/2017)
Who are some of Radius Health's key competitors?
Some companies that are related to Radius Health include ACADIA Pharmaceuticals (ACAD), Clovis Oncology (CLVS), Halozyme Therapeutics (HALO), Evotec (EVTCY), Puma Biotechnology (PBYI), China Biologic Products (CBPO), Amicus Therapeutics (FOLD), AnaptysBio (ANAB), Global Blood Therapeutics (GBT), Ascendis Pharma A/S (ASND), argenx SE - American Depositary Shares (ARGX), Immunomedics (IMMU), Emergent Biosolutions (EBS), Ultragenyx Pharmaceutical (RARE), Spark Therapeutics (ONCE), Horizon Pharma (HZNP), The Medicines (MDCO) and Crispr Therapeutics (CRSP).
Who are Radius Health's key executives?
Radius Health's management team includes the folowing people:
- Kurt C. Graves, Independent Chairman of the Board (Age 49)
- Jesper Hoiland, President, Chief Executive Officer, Director (Age 56)
- Jose Carmona, Chief Financial Officer, Principal Accounting Officer, Treasurer (Age 45)
- Gary Hattersley Ph.D., Senior Vice President, Chief Scientific Officer (Age 50)
- Brent Hatzis-Schoch, Senior Vice President, General Counsel, Secretary (Age 52)
- Lorraine A. Fitzpatrick M.D., Chief Medical Officer (Age 63)
- Gregory Williams Ph.D., Chief Development Officer (Age 58)
- Willard H. Dere M.D., Independent Director (Age 63)
- Catherine J. Friedman, Independent Director (Age 56)
- Jean-Pierre Garnier Ph.D., Independent Director (Age 69)
Has Radius Health been receiving favorable news coverage?
Media coverage about RDUS stock has been trending positive on Monday, Accern Sentiment reports. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Radius Health earned a daily sentiment score of 0.30 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 46.96 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
Who are Radius Health's major shareholders?
Radius Health's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Consonance Capital Management LP (5.94%), TimesSquare Capital Management LLC (4.20%), Franklin Resources Inc. (0.90%), Hudson Bay Capital Management LP (0.45%), Candriam Luxembourg S.C.A. (0.44%) and Eversept Partners LLC (0.44%). Company insiders that own Radius Health stock include Brent Hatzis-Schoch, Growth N V Biotech, Jesper Hoiland and Jose Carmona. View Institutional Ownership Trends for Radius Health.
Which institutional investors are selling Radius Health stock?
RDUS stock was sold by a variety of institutional investors in the last quarter, including Allianz Asset Management GmbH, Alliancebernstein L.P., ING Groep NV, Highland Capital Management LP, Franklin Resources Inc., Guggenheim Capital LLC, Metropolitan Life Insurance Co. NY and Rhumbline Advisers. View Insider Buying and Selling for Radius Health.
Which institutional investors are buying Radius Health stock?
RDUS stock was acquired by a variety of institutional investors in the last quarter, including Consonance Capital Management LP, TimesSquare Capital Management LLC, Eversept Partners LLC, Prosight Management LP, Crestline Management LP, Candriam Luxembourg S.C.A., Hudson Bay Capital Management LP and Alps Advisors Inc.. Company insiders that have bought Radius Health stock in the last two years include Brent Hatzis-Schoch, Growth N V Biotech, Jesper Hoiland and Jose Carmona. View Insider Buying and Selling for Radius Health.
How do I buy shares of Radius Health?
Shares of RDUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Radius Health's stock price today?
One share of RDUS stock can currently be purchased for approximately $35.18.
How big of a company is Radius Health?
Radius Health has a market capitalization of $1.62 billion and generates $22.11 million in revenue each year. The biopharmaceutical company earns $-254,230,000.00 in net income (profit) each year or ($5.80) on an earnings per share basis. Radius Health employs 561 workers across the globe.
How can I contact Radius Health?
Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-551-4000 or via email at [email protected]
MarketBeat Community Rating for Radius Health (RDUS)MarketBeat's community ratings are surveys of what our community members think about Radius Health and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Radius Health (NASDAQ:RDUS) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Hold|
|Consensus Rating Score: ||2.60||2.60||2.56||2.43|
|Ratings Breakdown: ||0 Sell Rating(s)|
4 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
4 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
4 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$52.22||$51.78||$48.00||$53.60|
|Price Target Upside: ||48.44% upside||47.26% upside||67.48% upside||45.51% upside|
Radius Health (NASDAQ:RDUS) Consensus Price Target History
Radius Health (NASDAQ:RDUS) Analyst Ratings History
(Data available from 3/19/2016 forward)
Radius Health (NASDAQ:RDUS) Earnings History and Estimates Chart
Radius Health (NASDAQ RDUS) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/1/2018||Q4 2017||($1.43)||($1.59)||$7.37 million||$7.66 million||View||Listen|
|11/2/2017||Q3 2017||($1.28)||($1.31)||$6.90 million||$13.50 million||View||N/A|
|8/3/2017||Q2 2017||($1.35)||($1.58)||$1.96 million||$0.98 million||View||Listen|
|8/12/2014||Q2||($0.89)||($2.22)||$16.24 million||$10.62 million||View||N/A|
Radius Health (NASDAQ:RDUS) Earnings Estimates
Current Year EPS Consensus Estimate: $-5.05 EPS
Next Year EPS Consensus Estimate: $-3.99 EPS
Dividend History for Radius Health (NASDAQ:RDUS)
No dividend announcements for this company have been tracked by MarketBeat.com
Radius Health (NASDAQ RDUS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 15.00%
Radius Health (NASDAQ RDUS) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|3/2/2018||Growth N V Biotech||Major Shareholder||Buy||80,000||$32.52||$2,601,600.00||5,853,799|| |
|2/9/2018||Growth N V Biotech||Major Shareholder||Buy||75,000||$34.38||$2,578,500.00||5,773,799|| |
|11/14/2017||Growth N V Biotech||Major Shareholder||Buy||50,000||$26.25||$1,312,500.00||5,698,799|| |
|11/10/2017||Brent Hatzis-Schoch||VP||Buy||1,778||$28.09||$49,944.02||2,278|| |
|11/7/2017||Jesper Hoiland||Insider||Buy||6,800||$29.04||$197,472.00||12,900|| |
|11/3/2017||Growth N V Biotech||Major Shareholder||Buy||50,000||$29.15||$1,457,500.00||5,648,799|| |
|10/25/2017||Growth N V Biotech||Major Shareholder||Buy||50,000||$32.85||$1,642,500.00||5,548,799|| |
|9/15/2017||Jesper Hoiland||Insider||Buy||6,100||$32.72||$199,592.00||6,100|| |
|9/14/2017||Growth N V Biotech||Major Shareholder||Buy||150,000||$33.45||$5,017,500.00||5,448,799|| |
|9/14/2017||Jose Carmona||CFO||Buy||3,000||$32.83||$98,490.00||3,000|| |
|9/12/2017||Growth N V Biotech||Major Shareholder||Buy||50,000||$35.42||$1,771,000.00||5,348,799|| |
|9/5/2017||Growth N V Biotech||Major Shareholder||Buy||50,000||$36.75||$1,837,500.00||5,298,799|| |
|8/16/2017||Growth N V Biotech||Major Shareholder||Buy||60,000||$35.98||$2,158,800.00||5,248,799|| |
|8/10/2017||Growth N V Biotech||Major Shareholder||Buy||150,000||$34.97||$5,245,500.00||5,113,799|| |
|5/30/2017||Growth N V Biotech||Major Shareholder||Buy||40,000||$34.21||$1,368,400.00||5,038,799|| |
|5/25/2017||Growth N V Biotech||Major Shareholder||Buy||40,000||$36.25||$1,450,000.00||4,998,799|| |
|5/18/2017||Growth N V Biotech||Major Shareholder||Buy||50,000||$34.41||$1,720,500.00||4,958,799|| |
|5/17/2017||Growth N V Biotech||Major Shareholder||Buy||35,000||$33.44||$1,170,400.00||4,890,799|| |
|5/12/2017||Growth N V Biotech||Major Shareholder||Buy||15,000||$34.00||$510,000.00||4,873,799|| |
|5/9/2017||Growth N V Biotech||Major Shareholder||Buy||50,000||$35.93||$1,796,500.00||4,858,799|| |
|5/8/2017||Growth N V Biotech||Major Shareholder||Buy||43,400||$35.57||$1,543,738.00||4,785,999|| |
|5/2/2017||Growth N V Biotech||Major Shareholder||Buy||75,000||$33.91||$2,543,250.00||4,765,399|| |
|5/1/2017||Growth N V Biotech||Major Shareholder||Buy||150,000||$35.39||$5,308,500.00||4,690,399|| |
|3/21/2017||Growth N V Biotech||Major Shareholder||Buy||50,000||$35.83||$1,791,500.00||4,540,399|| |
|3/17/2017||Growth N V Biotech||Major Shareholder||Buy||30,000||$38.41||$1,152,300.00||4,490,399|| |
|3/15/2017||Growth N V Biotech||Major Shareholder||Buy||61,721||$39.97||$2,466,988.37||4,415,930|| |
|3/10/2017||Growth N V Biotech||Major Shareholder||Buy||38,279||$39.17||$1,499,388.43||4,398,678|| |
|1/22/2016||Growth N V Biotech||Major Shareholder||Buy||38,259||$31.67||$1,211,662.53||4,360,399|| |
|1/13/2016||Growth N V Biotech||Major Shareholder||Buy||50,000||$39.90||$1,995,000.00||4,322,140|| |
|11/12/2015||Gary Hattersley||insider||Sell||5,683||$75.00||$426,225.00|| |
|11/3/2015||Gary Hattersley||insider||Sell||13,333||$70.00||$933,310.00|| |
|10/23/2015||Gary Hattersley||insider||Sell||11,302||$65.00||$734,630.00|| |
|10/21/2015||Gary Hattersley||insider||Sell||1,501||$65.36||$98,105.36|| |
|10/21/2015||Rob Ward||CEO||Sell||50,000||$61.99||$3,099,500.00|| |
|8/21/2015||Growth N. V. Biotech||major shareholder||Buy||100,000||$64.00||$6,400,000.00||4,272,140|| |
|8/17/2015||Kurt Graves||Director||Sell||22,694||$70.00||$1,588,580.00|| |
|7/6/2015||Kurt Graves||Director||Sell||25,000||$69.48||$1,737,000.00|| |
|6/18/2015||Kurt Graves||Director||Sell||25,000||$55.05||$1,376,250.00|| |
|5/1/2015||Growth N V Biotech||Major Shareholder||Buy||50,000||$36.46||$1,823,000.00|| |
|4/29/2015||Growth N V Biotech||Major Shareholder||Buy||50,000||$36.23||$1,811,500.00|| |
|4/28/2015||Growth N V Biotech||Major Shareholder||Buy||50,000||$36.59||$1,829,500.00|| |
|4/27/2015||Growth N V Biotech||Major Shareholder||Buy||50,000||$38.38||$1,919,000.00|| |
|3/6/2015||Growth N V Biotech||Major Shareholder||Buy||75,000||$47.08||$3,531,000.00|| |
|2/25/2015||Growth N V Biotech||Major Shareholder||Buy||35,000||$45.74||$1,600,900.00|| |
|6/11/2014||Morana Jovan-Embiricos||Director||Buy||587,500||$8.00||$4,700,000.00|| |
|6/6/2014||Growth N V Biotech||Major Shareholder||Buy||1,000,000||$8.00||$8,000,000.00|| |
Radius Health (NASDAQ RDUS) News Headlines
Radius Health (NASDAQ:RDUS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Radius Health (NASDAQ:RDUS) Income Statement, Balance Sheet and Cash Flow Statement
Radius Health (NASDAQ RDUS) Stock Chart for Monday, March, 19, 2018